A workshop was convened by the US Food and Drug Administration and the American Association for Cancer Research to create recommendations for trial design and later stages of drug development in multiple myeloma.
Researchers hope their findings could lead to targeted interventions to improve cognitive outcomes in pediatric brain tumor survivors from families with low socioeconomic status.
Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
New NCCN guidelines for Wilms tumor contain up-to-date information on screening, diagnosis, risk stratification, and treatment for this rare childhood renal cancer.
Xiuning Le, MD, PhD, discusses the future of tepotinib in the treatment of NSCLC. Dr Le is an author of a phase 2 study on tepotinib, a highly selective MET inhibitor.
Researchers discuss the potential of enobosarm, a selective androgen receptor modulator, for the treatment of ER-positive breast cancer that has progressed on at least 1 previous endocrine therapy.
A retrospective study found that a radiomic-clinicopathologic nomogram performed better than other tools in predicting biochemical recurrence-free survival after surgery for prostate cancer.
